

Suprachoroidal CLS-TA Plus Aflibercept Compared with Aflibercept Monotherapy for DME: *Primary and Selected Secondary Results of the Randomized Phase 2 TYBEE Trial*

Michael S. Ip, MD, Muneeswar Gupta Nittala and Swetha Velaga on behalf of the TYBEE Study Group

> The Doheny Image Reading Center Doheny Eye Institute University of California - Los Angeles



Disclosures

- Financial Disclosures
 - Consultant: Boehringer Ingelheim, ThromboGenics, Genentech, Astellas, Allergan, Novartis, Alimera, Allegro
- Study Disclosures
 - This study includes research conducted on human subjects. Institutional Review Board approval was obtained prior to study initiation



Analyses of Phase 3 clinical trial data have indicated that even what seems to be persistent DME initially, may have good long-term results

Outcomes of Diabetic Macular Edema Eyes with Limited Early Response in the VISTA and VIVID Studies

Dante Pieramici, MD,¹ Rishi P. Singh, MD,² Andrea Gibson, PhD,³ Namrata Saroj, OD,³ Robert Vitti, MD,³ Alyson J. Berliner, MD, PhD,³ Oliver Zeitz, MD,^{4,5} Carola Metzig, MD,⁴ Yuhwen Soo, PhD,³ Xiaoping Zhu, PhD,³ David S. Boyer, MD⁶

Ophthalmology Retina 2018 2, 558-566DOI: (10.1016/j.oret.2017.10.014)

Original Investigation


Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment

Susan B. Bressler, MD; Allison R. Ayala, MS; Neil M. Bressler, MD; Michele Melia, ScM; Haijing Qin, MS; Frederick L. Ferris III, MD; Christina J. Flaxel, MD; Scott M. Friedman, MD; Adam R. Glassman, MS; Lee M. Jampol, MD; Michael E. Rauser, MD; for the Diabetic Retinopathy Clinical Research Network JAMA Ophthalmol. 2016;134(3):278-285.




Protocol I: Median Visual Acuity

in Persistent DME Cohort






Real-world data suggests DME patients are undertreated



Ciulla et al – AAO 2019



Real-world outcomes are much worse than clinical trials in DME



Wecker et al (BJO 2016)



SCS Microinjector

Specifically for Suprachoroidal Delivery of Preservative Free Triamcinolone Acetonide (CLS-TA)




Illustration of CLS-TA Suprachoroidal Delivery

Goldstein TVST 2016


CLS-TA: Non-preserved, terminally sterilized, aqueous suspension of triamcinolone acetonide administered as a single injection of 4 mg in 0.1mL




Suprachoroidal Space (SCS) Delivery of Corticosteroids

- Maximize drug levels in retina
- Minimize drug levels in AC
- Potential to:
 - \circ $\,$ Reduce cataract acceleration $\,$
 - \circ $\,$ Reduce incidence of increased IOP $\,$


Greater Posterior & Less Anterior Exposure with SCS: Rabbit Eyes (Day 14)



Fluorescent particles s/p SCS injection in a pig eye




Triamcinolone acetonide s/p SCS injection in a rabbit eye



Olsen AJO 2006 Patel IOVS 2012 Edelhauser ARVO 2013



TYBEE Phase 2 Double-Masked 6-Month DME Trial




delivered into suprachoroidal space.

Aflibercept: 2 mg/0.05 mL

- Sham CLS-TA injections were administered to the aflibercept arm at Day 0 and Wk12.
- Sham aflibercept injections were administered to the combination arm at Wk4 and Wk8




Mean Change in BCVA






Steir Baseline BCVA: Aflibercept: 58; Combination 56




Baseline CST in microns: Aflibercept: 503; Combination 514 UCLA

≥2- and ≥3-Step DRSS Improvements at Week 24

50.0%



Combination treatment resulted in fewer treatment visits vs. aflibercept monotherapy





All Serious Adverse Events

Adverse Event Term	Aflibercept n (%)	Combination n (%)
Acute left ventricular failure	1 (2.9)	0 (0)
Acute myocardial infarction	1 (2.9)	0 (0)
Anemia	0 (0)	2 (5.6)
Cardiac arrest	0 (0)	1 (2.8)
Diabetes	0 (0)	1 (2.8)
Diabetic neuropathic ulcer	1 (2.9)	0 (0)
Fractures	0 (0)	2 (5.6)
Hepatorenal syndrome	0 (0)	1 (2.8)
Kidney disease	0 (0)	1 (2.8)
Orthostatic hypotension	0 (0)	1 (2.8)
Osteomyelitis	1 (2.9)	0 (0)
Pneumonia	0 (0)	3 (8.3)

No SAE assessed as related to study drug or study procedure in either arm



UCLA Stein Eye Institute

All Ocular Adverse Events

Adverse Event Term	Aflibercept n (%)	Combination n (%)
Conjunctival hemorrhage	1 (2.9)	2 (5.6)
Cataract*	1 (2.9)	2 (5.6)
Conjunctival opacity	0	1 (2.8)
Dry eye	0	1 (2.8)
Eye irritation	0	1 (2.8)
Eye pain	1 (2.9)	0
Macular hole	0	1 (2.8)
Ocular hypertension	0	1 (2.8)
Punctate keratitis	0	1 (2.8)
Retinal detachment	0	1 (2.8)
Retinal exudates	1 (2.9)	0
Visual acuity reduced	0	1 (2.8)
Vitreous detachment	1 (2.9)	0
Vitreous floaters	1 (2.9)	0
IOP increased	1 (2.9)	3 (8.3)
Sensation of foreign body	0	1 (2.8)
Visual field defect	0	1 (2.8)

* Includes "Cataract Nuclear"


Analysis: Disorganization of the Inner Retinal layers (DRIL)

Disorganization of the inner retinal layers was defined as the horizontal extent (μ m) for which 1 or more boundaries between the inner retinal layers (ganglion cell layer and inner plexiform layer complex, inner nuclear layer, and outer plexiform layer) were not separately identifiable




Spectralis OCT Case Illustration

Manual delineation of DRIL by snapping the outer plexiform layer to the inner limiting membrane in each B-scan of the macular volume.






Spectralis Case Illustration



A – B = DRIL Area Total Retina – Inner Retina = DRIL Area









DRIL area map from volume scans

Retinal thickness map







MRN: 4011-03 Patient: TYBEE, 4011-03 DateOfBirth: 1900-01-01 Gender: M StudyDate: 2017-09-14 19:48:59 Author: swetha

4

OD

Protocol: Volume ReportDate: 2019-03-21 12:36:17 AnnotationLastChangeDate: 1600-12-31 16:00:00 NumBScans: 49 Comment:

ILM -- Inner to Choroid -- Inner

Retina Thickness

 1
 Field No.
 Me

 5
 3
 2

 5
 4
 3

 4
 5
 6

 7
 6
 7

 8
 9
 6
 9


 7
 8
 9

 9
 Total Scan
 Very Center

Field No.	Mean (um)	Volume (mm^3)	Mean Intensity	Area (mm^2)	Dist to Max (mm)
1	307.1	1.55	0.5078	5.05	542.53
2	316.1	1.33	0.5402	4.20	541.28
3	292.3	1.29	0.5532	4.42	541.96
4	296.0	1.53	0.4872	5.18	542.60
5	445.6	0.70	0.3986	1.58	542.33
6	419.4	0.66	0.4382	1.57	541.56
7	446.4	0.70	0.4170	1.56	541.92
8	479.7	0.75	0.3513	1.57	542.39
9	639.9	0.50	0.2746	0.78	542.10
Total Scan	338.4	9.84	0.4761	29.03	542.40
Very Center	700.8	0.00	0.2133	0.00	542.07

A – B = DRIL Area Total Retina – Inner Retina = DRIL Area 29.03 – 26.64 = 2.39 mm2


ILM -- Inner to Outer Plexiform Layer -- Outer



Field No.	Mean (um)	Volume (mm^3)	Mean Intensity	Area (mm^2)	Dist to Max (mm)
1	158.9	0.80	0.5395	5.05	542.60
2	177.6	0.75	0.5817	4.14	541.60
3	151.2	0.67	0.6004	4.42	541.21
4	146.9	0.76	0.5164	5.18	543.63
5	120.9	0.19	0.5217	1.17	542.85
6	138.4	0.22	0.5404	1.40	541.43
7	125.1	0.20	0.5719	1.24	541.14
8	77.4	0.12	0.4776	0.91	542.77
9	0.7	0.00	0.5372	0.01	542.18
Total Scan	142.5	4.15	0.5548	26.64	530.45
Very Center	0.0	0.00	NaN	0.00	542.07


Inner Retina Thickness

Similar improvement in maximum extent of DRIL (µm)





Similar improvement in area of DRIL (mm²)





TYBEE: Conclusion

- Similar BCVA improvements with combination aflibercept & suprachoroidal CLS-TA treatment vs aflibercept monotherapy.
- CST improvement was significantly greater with combination treatment vs aflibercept monotherapy.
- Other anatomic outcomes such as DRSS and changes in *DRIL (maximum extent and area) were similar* when comparing combination aflibercept & suprachoroidal CLS-TA treatment vs aflibercept monotherapy.
- Fewer treatments in the combination arm compared to aflibercept monotherapy: 4.7 vs 2.8 mean treatment visits.



